Cho JH, Jin SY. Current guidelines for Helicobacter pylori treatment in East Asia 2022: Differences among China, Japan, and South Korea. World J Clin Cases 2022; 10(19): 6349-6359 [PMID: 35979311 DOI: 10.12998/wjcc.v10.i19.6349]
Corresponding Author of This Article
Jun-Hyung Cho, MD, PhD, Associate Professor, Digestive Disease Center, Soonchunhyang University Hospital, 59, Daesagwan-ro, Yongsan-gu, Seoul 04401, South Korea. chojhmd@naver.com
Research Domain of This Article
Gastroenterology & Hepatology
Article-Type of This Article
Minireviews
Open-Access Policy of This Article
This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
World J Clin Cases. Jul 6, 2022; 10(19): 6349-6359 Published online Jul 6, 2022. doi: 10.12998/wjcc.v10.i19.6349
Current guidelines for Helicobacter pylori treatment in East Asia 2022: Differences among China, Japan, and South Korea
Jun-Hyung Cho, So-Young Jin
Jun-Hyung Cho, Digestive Disease Center, Soonchunhyang University Hospital, Seoul 04401, South Korea
So-Young Jin, Department of Pathology, Soonchunhyang University Hospital, Seoul 04401, South Korea
Author contributions: Cho JH designed research; Cho JH and Jin SY performed research and literature review; Cho JH wrote the paper; Cho JH and Jin SY contributed critical revision and editing.
Supported bythe Soonchunhyang University Research Fund, No. 10210061.
Conflict-of-interest statement: The authors declare that they have no competing interests.
Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: Jun-Hyung Cho, MD, PhD, Associate Professor, Digestive Disease Center, Soonchunhyang University Hospital, 59, Daesagwan-ro, Yongsan-gu, Seoul 04401, South Korea. chojhmd@naver.com
Received: January 13, 2022 Peer-review started: January 13, 2022 First decision: March 8, 2022 Revised: March 11, 2022 Accepted: May 8, 2022 Article in press: May 8, 2022 Published online: July 6, 2022
Core Tip
Core Tip: Since 2000, the standard triple regimen containing clarithromycin (CAM) has been used as a legacy therapy to eradicate Helicobacter pylori (H. pylori). Resistance to CAM by H. pylori has increased to > 15% in East Asia. First-line eradication rates below 80% are strongly associated with CAM-resistant H. pylori strain emergence. H. pylori treatment guidelines in China, Japan, and South Korea were revised according to new data. In China, adding bismuth to H. pylori regimens was recommended as an empirical first-line treatment. In Japan, H. pylori treatment success increased when the potassium-competitive acid blocker (P-CAB) was introduced. In South Korea, tailored H. pylori eradication based on molecular testing for CAM resistance is used as the first-line treatment option. Dual therapy involving frequent administration of high-dose amoxicillin has shown good efficacy for H. pylori eradication in clinical trials. Furthermore, P-CABs, with their rapid and strong acid-suppressing activity, may contribute to successful H. pylori treatment in future.
